<DOC>
	<DOCNO>NCT02139371</DOCNO>
	<brief_summary>The primary objective study test new radiotracer call 64Cu-DOTA-AE105 PET image uPAR ( urokinase plasminogen activator receptor ) . The tracer potential identifying invasive cancer phenotype , thereby distinguish aggressive less aggressive tumor . This first human study test radiotracer cancer patient . The biodistribution tumor uptake evaluate repeated PET imaging ( 1,3 24 hour post injection ) .</brief_summary>
	<brief_title>Evaluation New Radiotracer ( 64Cu-DOTA-AE105 ) Diagnosing Aggressive Cancer With Positron Emission Tomography</brief_title>
	<detailed_description>The primary objective study test new radiotracer call 64Cu-DOTA-AE105 PET image uPAR ( urokinase plasminogen activator receptor ) . The tracer potential identifying invasive cancer phenotype , thereby distinguish aggressive less aggressive tumor . This first human study test radiotracer cancer patient . The biodistribution tumor uptake evaluate repeated PET imaging ( 1,3 24 hour post injection ) . The primary end point Biodistribution dosimetry 64Cu-DOTA-AE105 . In addition , quantitative uptake 64Cu-DOTA-AE105 tumor expression uPAR tumor tissue obtain surgery biopsy ( either 14 day ( biopsy ) PET scan ) compare validate image-derived data UPAR expression</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>clinical diagnosis cancer prostate , breast urinary bladder capable understanding give full inform consent pregnancy lactation contraindication use intravenous CT contrastagencies claustrophobia current/or former diagnose cancer , except non melanoma skin cancer carcinoma situ cervicis uterus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Uroplasminogen Plasminogen Activator Receptor</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Urinary bladder cancer</keyword>
	<keyword>Biodistribution</keyword>
	<keyword>Radiation exposure</keyword>
</DOC>